The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
life is hard, but we have all invested in here to make our lives better, and for new investors look at the interviews from the DOB they are passionate about the products and have a proven track record. good luck all and to top it off AGM tomorrow.
It must be distressing. I have a 3yr old, I can't imagine how you must feel.
Lets wish companies like this success.
KR
lupus, autoimmune inflammatory diseases, these are also treated with Inflixmab and cyclophosphamide a strong chemo which you have to be hydrated for one day then cyclophosphamide the next day and then re-hydrated the day after, so a 3 day hospital addmision. also Mycophenolate mofetil (MMF) this is used (this is a transplant rejection drug.)
Tell you what these are the dieases Charlotte has so i know what i am saying Systemic vasculitis, Ulcerative colitis, Primary Sclerosing Cholangitis (PSC), lupus, and high Intracranial Pressure, she became sick when she was 4
Thanks, Phase 2 test Foralumab Q2 2021 for Crones or Crohn's sounds huge.
Actually, everything he said sounded big & surprisingly accessible.
I'll have a another listen to latch on to what he said to expect in the near future.
https://www.tizianalifesciences.com/news-item?s=2020-07-10-tiziana-life-sciences-interview-to-air-on-bloomberg-international-on-the-redchip-money-report
the drugs on the market at the moment for Crones is • Immunosuppressants suppress the immune system, and reduce levels of inflammation. The main immunosupressants used in IBD are:
• Azathioprine and Mercaptopurine which is chemo.
• Methotrexate
Mycophenolate mofetil, ciclosporin, and tacrolimus are also used.
• Biological drugs are the newest group of drugs used to treat Crohn’s. These include:
• Infliximab
• Adalimumab
• Golimumab
• Ustekinumab
all these drugs in injected, and Infliximab is a intravenous infusion, the problem with these drugs is the side effects and long term use can lead to other cancers. So a new phase 2 study is will be completed in 2nd quarter 2021, i can go on and on about these drugs because i have first hand knowledge and see what effect the illnesses have and the effects the drugs have.
I have no knowledge of MS, liver disease i do for most the the Liver Disease there is nothing on the market, Ursodeoxycholic acid is used most, and this is used to make sure bile can flow when the ducks are restricted this helps with slowing the build up in the liver, as once you go into liver failure you have 42 day for a transplant, but for most disease transplant still wont work.
I was a bit unclear on what he said about news in the near future, can I check your take
a) MS - test of nasal application (of Foralumab?) underway at Harvard by Howard Weiner, expect test data July/Aug 2020
b) Liver cancer - oral application(of Foralumab?) , data end July 2020 (also at Harvard?)
The Tiziana web site says it has 3 main "compounds" - medicinal compounds presumably.
Miliciclib (TZLS-201) - blocks cyclin dependent kinases CDKs in cell division, successful in phase 2 trials for epithelial thymic carcinoma & thymona (I looked them up - rare thoracic cancers 1.3 - 2.3 per million) + phse 2a data on sorafenib resistant HCC patients.
Foralumab (TZLS-401) - a anti-human CD3 antibody to reduce immunogenicity (reaction to foreign substance/i.e. other medicines) and prevention of cytokine release syndrome (like in Covid cytokine storm) that the company has novel ways of application oral, nasal & inhalation. Mentions treatment for Crohn's disease. NASH (Non Alcoholic SteatoHepatitis - i.e. when Kunwar talks about liver disease?), Neurodegenerative disease (i.e. when he talks about MS?)
Anti Interleukin 6 receptor IL-6R (TZLS - 501) - licenced from Novimmune has potential to treat acute respiratory distress syndrome ARDS, arthritis, lupus, autoimmune inflammatory diseases & oncology indications.
have just be re-watching the interview, the studies they are doing on Crones and MS is because the big pharms have asked them for these particular studies, the drugs TILS have shall i say are ground braking/life saving and the results will be in 2 quarter of 2021, thats no time at all. He said the BOD are looking out for shareholders regarding StemPrintER so sit back and enjoy the pizza be it 6" or 12" may it be deep pan or stuffed crust and you can have as many toppings as you like. and i think at this price Tils is worth investing in, so much i did 2 top ups yesterday.